TY  - CHAP
M1  - Book, Section
TI  - Pharmacotherapy of Inflammatory Bowel Disease
A1  - Hilal-Dandan, Randa
A1  - Brunton, Laurence L.
PY  - 2016
T2  - Goodman and Gilman's Manual of Pharmacology and Therapeutics, 2e
AB  - Inflammatory  bowel  disease  (IBD)  is  a  spectrum  of  chronic,  idiopathic,  inflammatory  intestinal  conditions.  IBD  causes  significant  gastrointestinal  (GI)  symptoms  that  include  diarrhea,  abdominal  pain,  bleeding,  anemia,  and  weight  loss.  IBD  conventionally  is  divided  into  2  major  subtypes:  ulcerative  colitis  and  Crohn  disease.  Ulcerative  colitis  is  characterized  by  confluent  mucosal  inflammation  of  the  colon  starting  at  the  anal  verge  and  extending  proximally  for  a  variable  extent  (e.g.,  proctitis,  left-sided  colitis,  or  pancolitis).  Crohn  disease,  by  contrast,  is  characterized  by  transmural  inflammation  of  any  part  of  the  GI  tract  but  most  commonly  the  area  adjacent  to  the  ileocecal  valve.  The  inflammation  in  Crohn  disease  is  not  necessarily  confluent,  frequently  leaving  "skip  areas"  of  relatively  normal  mucosa.  The  transmural  nature  of  the  inflammation  may  lead  to  fibrosis  and  strictures  or  fistula  formation.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessbiomedicalscience.mhmedical.com/content.aspx?aid=1127552942
ER  -